The advent of biological therapies over the past decade has initiated a new therapeutic era for the treatment of Crohn’s disease (CD), especially for patients with corticosteroid-dependent, corticosteroid-refractory or fistulizing disease. For years the primary goal of traditional therapies has been the control of disease-related symptoms. However, emerging evidence from inflammatory bowel disease (IBD) research suggests that the new biological agents not only control symptoms but may also alter the natural history of the disease. Accordingly, the therapeutic goals in the medical treatment of CD are changing and now include the rapid induction of clinical remission, the maintenance of steroid-free clinical remission, the healing of mucosal lesions, improvements in health-related quality of life, and a reduction in both the need for surgery and hospital stay.
KeywordsProgressive Multifocal Leukoencephalopathy Progressive Multifocal Leukoencephalopathy Episodic Treatment Certolizumab Pegol Charm Trial
Unable to display preview. Download preview PDF.
- 6.Sanborn W, Rutgeerts P, Reinisch et al (2008) SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 103:1117 (Abstract)Google Scholar